Inventor · disambiguated record
Jingtai Cao
Also filed as: CAO JINGTAI
13 granted patents·6 pending applications·231 citations·filing 2004–2021
91Inventor score
Top patents by PatentIndex Score
19 records- 0198US7531173B2Ophthalmic composition of a VEGF antagonistREGENERON PHARMA·Filed 2007·Granted May 12, 2009·109 cites·2 claims
- 0297US9795121B2Humanized C3 animalsREGENERON PHARMA·Filed 2015·Granted Oct 24, 2017·18 cites·23 claims
- 0397US7303748B2Method of treating eye injury with local administration of a VEGF inhibitorREGENERON PHARMA·Filed 2006·Granted Dec 4, 2007·49 cites·10 claims
- 0495US7378095B2Methods of treating type I diabetes by blocking VEGF-mediated activityREGENERON PHARMA·Filed 2005·Granted May 27, 2008·24 cites·5 claims
- 0587US10492477B2Humanized C5 animalsREGENERON PHARMA·Filed 2017·Granted Dec 3, 2019·2 cites·26 claims
- 0686US11178860B2Humanized C5 animalsREGENERON PHARMA·Filed 2019·Granted Nov 23, 2021·1 cites·20 claims
- 0785US7300654B2Method of treating corneal transplant rejection in high risk keratoplasty patientsREGENERON PHARMA·Filed 2005·Granted Nov 27, 2007·8 cites·4 claims
- 0882US7300653B2Method of treating corneal transplant rejectionREGENERON PHARMA·Filed 2004·Granted Nov 27, 2007·19 cites·8 claims
- 0979US11064685B2Non-human animal models of retinoschisisREGENERAN PHARMACEUTICALS INC·Filed 2018·Granted Jul 20, 2021·1 cites·29 claims
- 1077US2022132818A1Humanized c5 animalsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1171US10524458B2Humanized C3 animalsREGENERON PHARMA·Filed 2018·Granted Jan 7, 2020·0 cites·24 claims
- 1270US12082565B2Non-human animals models of retinoschisisREGENERON PHARMA·Filed 2021·Granted Sep 10, 2024·0 cites·26 claims
- 1366US11071780B2Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumabREGENERON PHARMA·Filed 2018·Granted Jul 27, 2021·0 cites·9 claims
- 1453US2005129685A1Use of IL-1 blockers to prevent corneal inflammation and neovascularizationFiled 2004·Application pending·0 cites
- 1549US2017080086A1Methods and formulations for treating vascular eye diseasesREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 1646US2016144025A1Methods and formulations for treating vascular eye diseasesREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 1745US11104730B2Methods of treating eye disorders with APLNR antagonists and VEGF inhibitorsREGENERON PHARMA·Filed 2018·Granted Aug 31, 2021·0 cites·46 claims
- 1842US2016152717A1Methods for treating dry eye disease by administering an il-6r antagonistREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 1935US2017360013A1Animal model for dry eye and methods of use of such animalsREGENERON PHARMA·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →